Home・Aandelen Lijst・Pacira Pharmaceuticals Inc-DE

Pacira Pharmaceuticals Inc-DE

Gesloten

SectorGezondheidszorg

27.59 3.41

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

26.19

Max

27.59

Belangrijke statistieken
By Trading Economics
Inkomsten	1.3M 2.9M
Verkoop	-19M 177M
K/W Sectorgemiddelde	207.077 68.51
EPS	0.6
Winstmarge	1.644
Werknemers	825
EBITDA	5M 30M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+17.64% upside

Dividenden
By Acuity
Volgende Winsten	5 nov 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-40M 1.1B
Vorige openingsprijs	24.18
Vorige sluitingsprijs	27.59

Nieuwssentiment

By Acuity

50%

175 / 340 Rangschikking in Healthcare

Pacira Pharmaceuticals Inc-DE Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

4 aug 2026, 19:53 UTC

Pacira Biosciences Inc is higher today, supported by overall market strength and a decline in crude oil prices easing inflation concerns.

3 aug 2026, 20:06 UTC

Pacira Biosciences Inc. shares are higher today, reflecting broader market gains led by major stocks, despite no specific company news identified.

31 jul 2026, 20:02 UTC

Pacira Biosciences Inc's shares are lower today, reaching a session low earlier. The price remains above its 20-day moving average despite the decline.

30 jul 2026, 17:16 UTC

Pacira Biosciences is advancing during Thursday's session, regaining momentum after earlier pulling back from a session high amid broader market optimism.

29 jul 2026, 20:04 UTC

Shares of Pacira Biosciences Inc. are lower today, continuing a decline since Tuesday's close. The stock reached an early high before falling significantly.

28 jul 2026, 19:56 UTC

Event

News

Shares of Pacira Biosciences Inc. are higher, driven by survey findings on orthopedic pain's impact on the workforce and strong interest in non-opioid treatments.

27 jul 2026, 18:51 UTC

Event

News

Pacira Biosciences advances PCRX-201 to commercial manufacturing, allowing patient enrollment in Phase 2 ASCEND study. Shares are higher as investor confidence strengthens.

24 jul 2026, 17:16 UTC

Pacira Biosciences Inc shares are lower today, with no specific news driving the decline. Broader market sentiment is impacted by falling crude oil prices.

22 jul 2026, 18:06 UTC

Pacira Biosciences Inc shares are lower in Wednesday's session, pulling back from earlier gains amid broader market caution and rising crude oil prices.

21 jul 2026, 19:56 UTC

Pacira Biosciences Inc is trading higher, reflecting broader market interest in technology and AI sectors ahead of upcoming earnings reports.

20 jul 2026, 19:46 UTC

Pacira Biosciences Inc shares are trading lower today, having retraced from an earlier high. No specific news was identified to explain the decline.

Peer Vergelijking

Prijswijziging

Pacira Pharmaceuticals Inc-DE Prognose

Koersdoel

By TipRanks

17.64% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 31.67 USD 17.64%

Hoogste 38 USD

Laagste 25 USD

Gebaseerd op 3 Wall Street-analisten die 12-maands prijsdoelen bieden voor Pacira Pharmaceuticals Inc-DE - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

3 ratings

Buy

Hold

Sell

Gebaseerd op 3 analisten die aandelenratings hebben gegeven aan Pacira Pharmaceuticals Inc-DE - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

175 / 340 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Pacira Pharmaceuticals Inc-DE

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.